Skip to content
Tenfell
Awarded contract
Published 20 Jul 2022

Hereditary Angioedema

NHS England · London

Key facts

Awarded
19 Jun 2022
Contract starts
30 Jun 2022
Contract ends
31 Dec 2023
Procedure
Open procedure (above threshold)
Buyer type
Central government

Awarded to 10 suppliers

SupplierValue
Takeda UK Limited—
Celix Pharma Ltd.—
Martindale Pharma—
Wockhardt UK Limited—
Accord-UK Ltd—
Cipla Limited—
CSL Behring UK Ltd—
Piramal Critical care Limited—
BioCryst Ireland Limited—
Pharming Group—

Description

NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema. Period of framework agreement: 1 July 2022 to 31 December 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 30 months. Total maximum framework agreement including extension options will be no more than 48 months

Categories (CPV)

Similar open tenders

About NHS England

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Their other open tenders

Published by the buyer on Contracts Finder archive (Open Contracting) (Open Government Licence v3.0). Always read the original notice before responding.